A 13-week clinical trial investigating the anti-aging drug rapamycin, combined with exercise, yielded negative results in humans. The study, co-funded by VitaDAO, aimed to explore the potential of this lifespan-extending compound. Dr. Brad Stanfield, the trial leader, reported the findings, suggesting further research is required despite promising animal data. This outcome adds to the complexity of translating longevity research from lab to practical application.